CSF3 and plasma cell myeloma: In conclusion, being aware of the limitations discussed above, from our study biosimilar Peg-filgrastim seems to be as effective as the originator and more effective than short-acting G-CSF formulations (Lenograstim and biosimilar Filgrastim) in terms of post-transplant engraftment in myeloma and lymphoma patients undergoing ASCT.